[8-K] RCI Hospitality Holdings, Inc. Reports Material Event

Rhea-AI Filing Summary

Viracta Therapeutics, Inc. (Nasdaq: VIRX) has been slated for removal from the Nasdaq Stock Market. Nasdaq filed a Form 25 on 10 July 2025 to strike the company’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. The exchange certifies that it meets all requirements of 17 CFR 240.12d2-2(b) for delisting and that the issuer and exchange have complied with applicable rules. The notice was signed by Hearings Advisor Aravind Menon. No financial results, earnings data, or additional corporate context are provided in this filing.

The delisting will end Nasdaq trading in VIRX shares and terminate their Section 12(b) registration. Investors should expect the shares to trade on an over-the-counter venue or another qualified market once the Form 25 becomes effective.

Positive

• None.

Negative

• Nasdaq delisting of Viracta Therapeutics common stock will end exchange trading, curtailing liquidity and institutional participation.
• Loss of Section 12(b) registration may increase compliance costs and reduce transparency for investors.

Insights

Securities Analyst

TL;DR: Nasdaq is delisting Viracta; liquidity and visibility will drop—clear negative.

Form 25 filings usually become effective 10 days after submission, at which point the issuer’s shares cease Nasdaq trading and Section 12(b) registration ends. Delisting reduces liquidity, analyst coverage, and institutional ownership potential, often pressuring the share price. Because no mitigating information (e.g., up-list plans or balance-sheet improvements) accompanies the notice, the development is materially adverse for current equity holders.

Corporate Governance Expert

TL;DR: Exchange-initiated or voluntary, the filing confirms regulatory compliance but signals governance challenges.

The Form 25 states that both Nasdaq and the issuer have complied with Rule 12d2-2 requirements. While procedural adherence is positive, delisting suggests the company failed to maintain listing standards—commonly related to market-cap, price, or reporting issues. Governance focus now shifts to ensuring transparent communication with shareholders regarding post-Nasdaq trading arrangements and any remedial listing strategy.

FALSE000093541900009354192025-07-102025-07-10

United States

Securities and Exchange Commission

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 10, 2025

RCI HOSPITALITY HOLDINGS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Texas			001-13992			76-0458229
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

10737 Cutten Road

Houston, Texas 77066

(Address of Principal Executive Offices, Including Zip Code)

(281) 397-6730

(Issuer’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.01 par value

RICK

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On July 10, 2025, we issued a press release announcing sales at nightclubs and restaurants for the third fiscal quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this current report on Form 8-K.

This information shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit Number						Description
99.1						Press release of RCI Hospitality Holdings, Inc. dated July 10, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			RCI HOSPITALITY HOLDINGS, INC.
Date: July 10, 2025			By:			/s/ Eric Langan
						Eric Langan
						President and Chief Executive Officer

3

FAQ

Why is Viracta Therapeutics (VIRX) being delisted from Nasdaq?

The Form 25 indicates Nasdaq has filed to remove VIRX common stock from listing and registration under Rule 12d2-2; specific listing-standard breaches are not disclosed.

When will the VIRX delisting become effective?

Form 25 filings generally become effective 10 days after filing (10 July 2025), unless withdrawn.

Where will VIRX shares trade after Nasdaq delisting?

The filing does not specify, but delisted shares typically move to over-the-counter (OTC) markets.

Does the Form 25 include any financial results or earnings data for Viracta Therapeutics?

No. The document is purely a regulatory notice and provides no financial or operational metrics.

Who signed the Nasdaq Form 25 for Viracta Therapeutics?

Hearings Advisor Aravind Menon signed the filing on behalf of Nasdaq Stock Market LLC.